TipRanks
Advertisement
Advertisement

MX:TAKN Stock Latest News

Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
The FlyTakeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
7d ago
TAK
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
PremiumThe Fly
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
7d ago
TAK
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
PremiumThe Fly
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
8d ago
DNA
TAK
Keros Therapeutics to receive $20M development milestone payment from Takeda
PremiumThe Fly
Keros Therapeutics to receive $20M development milestone payment from Takeda
8d ago
TAK
KROS
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
PremiumThe Fly
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
10d ago
TAK
Takeda announces FDA acceptance of zasocitinib under priority review
PremiumThe FlyTakeda announces FDA acceptance of zasocitinib under priority review
23d ago
TAK
Takeda announces publication of data from Phase 3 studies of oveporexton
Premium
The Fly
Takeda announces publication of data from Phase 3 studies of oveporexton
28d ago
TAK
Protagonist Therapeutics announces $300M share repurchase program
Premium
The Fly
Protagonist Therapeutics announces $300M share repurchase program
29d ago
JNJ
TAK
Keros Therapeutics announces $5M share repurchase program after Takeda payment
PremiumThe Fly
Keros Therapeutics announces $5M share repurchase program after Takeda payment
29d ago
TAK
KROS
Trump Trade: President warns communities against rejecting data centers
PremiumThe Fly
Trump Trade: President warns communities against rejecting data centers
1M ago
AZN
LLY
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
1M ago
TAK
PTGX
Bayer, Takeda expected to announce new pricing deals with White House, FT says
PremiumThe Fly
Bayer, Takeda expected to announce new pricing deals with White House, FT says
1M ago
AZN
LLY
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
PremiumThe FlyProtagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
1M ago
TAK
PTGX
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
Premium
The Fly
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
1M ago
TAK
PTGX
Takeda receives FDA approval of NDA for Mimrylo
Premium
The Fly
Takeda receives FDA approval of NDA for Mimrylo
1M ago
TAK
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
PremiumThe Fly
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
1M ago
SNY
TAK
Takeda announces Japan MHLW approval for Orzeyful
PremiumThe Fly
Takeda announces Japan MHLW approval for Orzeyful
1M ago
TAK
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
PremiumRatings
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
2M ago
TAK
Takeda award from Veterans Affairs posted to SAM.gov site
PremiumThe Fly
Takeda award from Veterans Affairs posted to SAM.gov site
2M ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
PremiumThe FlyFDA approves Takeda’s Orzeyful to treat narcolepsy type 1
2M ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
Premium
The Fly
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
2M ago
TAK
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
Premium
Company Announcements
Takeda Earnings Call: FX Tailwinds, Pipeline Firepower
2M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >